Monday, August 31, 2026

Moderna Stock Slids Again On Wednesday

ViaNews Editorial Team

November 18, 2020

Moderna Stock Slids Again On Wednesday
Shares of Moderna dropped 4.06% to $89.37 at 13:05 EST on Wednesday. The Nasdaq Stock Market jumped 0.25% to $11929.2, on what seems at the moment an all-around somewhat positive exchanging session for Wall Street. Moderna last close was $93.15, below its 52-week high of $103.2. Moderna's sales growth is 1074.4% for the current quarter and 2299% for the next. The company's growth estimates for the current quarter and the next is a negative 73% and a positive 142.9%, respectively. Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months. Moderna's stock is valued at $89.37 at 18:05 EST, way below its 52 Week High of $103.2 and way higher than its 52 Week Low of $17.68. Moderna's value is way above its 50 day moving average of $74.25. Moderna's worth is way higher than its 200 day moving average of $68.61.
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Hawkish Fed Signals at Jackson Hole Pressure Rate-Sensitive Assets
Kevin Warsh's hawkish inflation remarks at Jackson Hole, alongside a steady drumbeat of Federal Reserve testimony from Powell, Barr, Bowman and other officials on supervision, regulation and monetary policy, signal continued vigilance against inflation rather than an imminent easing cycle. Rate-sensitive and precious-metals-linked names such as SSR Mining sold off the same day, consistent with markets repricing for a firmer-for-longer policy stance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,261 source documents archived
Query this data → isubstrate.com